Medigene AG MDGEF
2.59 USD 0.00 (+0.00%)
At closeMay 14, 2026, 4:00 PM EDT
0.10 Day range 2.59
0.10 52-week range 2.59
- YTD
- 0.00%
- 1 year
- 0.00%
News
globenewswire.com Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S. Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided…
globenewswire.com Medigene AG announces closing of its first SEPA tranche Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
globenewswire.com Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
globenewswire.com Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc. Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
globenewswire.com Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021 Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
globenewswire.com Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
globenewswire.com Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024 Number of shares issued decreases from 29,475,189 to 14,737,594 due consolidation of the shares at a ratio of 2:1 Consolidation of shares to take place on August 29, 2024 Planegg/Martinsried, August…
seekingalpha.com Medigene AG (MDGEF) Q2 2024 Earnings Call Transcript Medigene AG (OTCPK:MDGEF) Q2 2024 Earnings Conference Call August 14, 2024 9:30 AM ET Company Participants Pamela Keck - Head, IR Selwyn Ho - CEO Conference Call Participants Joe Pantginis - H.C.…
globenewswire.com Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update Significant corporate and scientific progress in the first half of 2024 Advancement of lead program MDG1015 with IND filing on track for 3Q 2024 and CTA filing for 4Q 2024 New additions to End-to-End…
globenewswire.com Medigene AG to Report Half-Year 2024 Financial Results on August 14, 2024 Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
prnewswire.com WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary…
globenewswire.com Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and WuXi Biologics (stock code: 2269.HK) enter into a three-year, multi-target strategic partnership to design…
globenewswire.com Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell…
globenewswire.com Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell…
globenewswire.com Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated…
globenewswire.com Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise Cash runway extended into July 2025 from previously April 2025 Capital raise strengthens Medigene's financial position Lead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q…
globenewswire.com Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell…
globenewswire.com Medigene AG reports Financial Results and Business Update for Q1 2024 Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell…
globenewswire.com Medigene AG Secures European Patent for its iM-TCR Technology Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for…
seekingalpha.com Medigene AG (MDGEF) Full Year 2023 Earnings Call Transcript Medigene AG (MDGEF) Full Year 2023 Earnings Call Transcript
benzinga.com Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy